#China #Shanghai #WuXi Biologics #Candid Therapeutics #T-cell Engager

WuXi Biologics Partners with Candid Therapeutics

WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has recently unveiled a groundbreaking partnership with Candid Therapeutics, a biotechnology firm specializing in T-cell engineers for autoimmune conditions. This collaboration is set to enhance the treatment landscape for autoimmune diseases through innovative therapies.

The Agreement

On January 6, 2025, WuXi Biologics announced that Candid Therapeutics will have exclusive worldwide rights to a preclinical trispecific T-cell engager derived from WuXi's proprietary WuXiBody™ platform, renowned for its capabilities in developing various multispecific antibodies. This agreement promises WuXi Biologics potential upfront payments and developmental milestones that could reach as high as $925 million, alongside attractive royalties based on sales.

Advancements in T-cell Technology

Dr. Chris Chen, the CEO of WuXi Biologics, expressed enthusiasm about the collaboration, highlighting the dual advantage of not only aiding Candid's advancement of T-cell engagers but also reinforcing WuXi's stature as a premier partner in next-generation biological technologies. He emphasized that this partnership forms part of a broader strategy that has already enabled multiple global programs driving molecule discovery, aligning with WuXi's vision of delivering innovative solutions to patients worldwide.

Dr. Ken Song, the Chairman of Candid Therapeutics, added that the agreement solidifies Candid's position as a leader in the development of T-cell engagers targeting B-cells, specifically those involved in autoimmune diseases. He noted that Candid is particularly excited to leverage WuXi's technological advancements to explore the capabilities of their engineered biologics in clinical settings.

WuXiBody™ Platform

WuXi's WuXiBody™ platform is designed to foster the development of multispecific antibodies tailored to meet the growing global demand for more sophisticated therapeutic options. It is engineered to surpass challenges related to drug discovery and manufacturing, a common hurdle in the biotechnology field. The platform not only promises improved stability, solubility, and purification processes but also aims to minimize immunogenicity risks while extending the drug's effective duration in the body.

The structural adaptability of WuXiBody™ allows for customized formats, accommodating various combinations for different therapeutic needs. This cutting-edge platform is pivotal for enabling rapid progression through discovery phases, substantially cutting down developmental timelines and costs.

Company Profiles

WuXi Biologics

Established on a firm commitment to delivering end-to-end solutions for biologics, WuXi Biologics integrates its vast expertise across various locations, including the United States, Germany, Ireland, Singapore, and China. Currently supporting numerous projects, the organization is keen on maintaining its leadership stance in biopharmaceutical manufacturing while adhering to stringent Environmental, Social, and Governance (ESG) standards.

Candid Therapeutics

Founded in 2024 and headquartered in San Diego, Candid Therapeutics aspires to lead in the T-cell engager market, focusing on treatments that deplete B-cells to address autoimmune diseases. With a dynamic team adept at advancing clinical programs, Candid is gearing up to make significant contributions to the evolving field of immunotherapeutics.

Conclusion

The collaboration between WuXi Biologics and Candid Therapeutics marks a significant milestone in biopharmaceuticals. By harnessing WuXi's advanced platforms and Candid’s dedicated focus on T-cell engagers, the partnership aims to pioneer effective therapies for autoimmune conditions. This alliance not only underscores their commitment to scientific excellence but also reflects a shared vision of enhancing patient outcomes across the globe.